4D Molecular (FDMT) earnings history
Most recent quarter
- Fiscal period
- Q3 2025
- Period end
- Sep 30, 2025
- EPS actual
- −$1.01
- EPS estimate
- −$0.98
- EPS surprise
- −2.79%
- Revenue surprise
- −68.73%
- Revenue
- $90,000.00
- Revenue estimate
- $287,857.00
- Reported
- Nov 10, 2025
4D Molecular's most recent quarter in the table is Q3 2025, reported November 10, 2025. It posted a loss of $1.01 per share, slightly wider than the $0.98 loss expected, a 2.79% miss. Revenue was $90,000 against a $287,857 estimate. A year earlier, in Q3 2024, the loss was $0.79 per share on revenue of $3,000. The nine-month loss was $2.85 per share, against $2.08 a year earlier.
Every one of the 18 quarters in the table was a loss. Annual losses were $2.48 per share in 2021, $3.32 in 2022 and $2.97 in 2024; the table has no Q4 2023 row. Revenue has been small and uneven. The largest amounts were $20.2 million in Q3 2023 and $14.6 million in Q2 2021, and those were also the two smallest losses, at $0.24 and $0.28 per share. Q3 2025 was the widest loss in the table. Against estimates there were 9 beats, 8 misses and one match.
In past years the Q4 report came between late February and late March. The table does not yet show a quarter newer than Q3 2025. The next update will show whether losses keep widening.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q3 2025 | Nov 10, 2025 | −$0.98 | −$1.01 | −2.79% | $90,000.00 | SEC |
| Q2 2025 | Aug 11, 2025 | −$0.73 | −$0.98 | −34.74% | $15,000.00 | SEC |
| Q1 2025 | May 8, 2025 | −$0.87 | −$0.86 | +1.24% | $14,000.00 | SEC |
| Q4 2024 | Feb 28, 2025 | −$0.84 | −$0.89 | −6.52% | $500.00 | SEC |
| Q3 2024 | Nov 13, 2024 | −$0.68 | −$0.79 | −16.88% | $3,000.00 | SEC |
| Q2 2024 | Aug 8, 2024 | −$0.68 | −$0.63 | +7.92% | $5,000.00 | SEC |
| Q1 2024 | May 9, 2024 | −$0.74 | −$0.66 | +10.92% | $0.00 | SEC |
| Q3 2023 | Nov 9, 2023 | −$0.61 | −$0.24 | +60.87% | $20.2M | SEC |
| Q2 2023 | Aug 9, 2023 | −$0.78 | −$0.77 | +1.76% | $239,000.00 | SEC |
| Q1 2023 | May 11, 2023 | −$0.89 | −$0.88 | +1.49% | $298,000.00 | SEC |
| Q4 2022 | Mar 15, 2023 | −$0.79 | −$0.84 | −6.91% | $1.2M | SEC |
| Q3 2022 | Nov 8, 2022 | −$0.84 | −$0.79 | +6.40% | $500,000.00 | — |
| Q2 2022 | Aug 11, 2022 | −$0.85 | −$0.87 | −2.84% | $162,000.00 | SEC |
| Q1 2022 | May 12, 2022 | −$0.81 | −$0.82 | −0.92% | $1.2M | SEC |
| Q4 2021 | Mar 28, 2022 | −$0.85 | −$0.85 | +0.00% | $96,000.00 | SEC |
| Q3 2021 | Nov 10, 2021 | −$0.81 | −$0.82 | −1.23% | $1.4M | SEC |
| Q2 2021 | Aug 12, 2021 | −$0.68 | −$0.28 | +58.82% | $14.6M | SEC |
| Q1 2021 | May 13, 2021 | −$0.83 | −$0.53 | +36.14% | $2.0M | SEC |
Quarterly revenue
Frequently asked questions
When did 4D Molecular (FDMT) last report earnings?
4D Molecular last reported on Nov 10, 2025, covering fiscal Q3 2025.
Did FDMT beat earnings estimates?
No. 4D Molecular reported EPS of −$1.01 for Q3 2025 against a −$0.98 estimate — a 2.79% miss.
How much revenue did FDMT report last quarter?
4D Molecular reported $90,000.00 in revenue for Q3 2025, against a consensus estimate of $287,857.00.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.